CALPRO AS
Operating
Plasma and serum calprotectin immunoassay Calprotectin blood test - S100A8/A9 Heterodimer
Measurement of calprotectin in blood (plasma and serum) in the assessment of inflammation and severe infection on clinical chemistry systems
Forskning og utvikling av nye medisinske tester, produksjon av
reagenser og råvarer, omsetning av medisinske tester og tilhørende
produkter og tjenester, salg eller utleie av informasjoner og
rettigheter, samt deltakelse i selskap som driver tilsvarende
virksomheter.
Forskning og utvikling av nye medisinske tester, produksjon av
råvarer, omsetning av medisinke tester og tilhørende produkter og
tjenester, salg eller utleie av informasjoner og rettigheter, samt
deltakelse i selskap som driver tilsvarende virksomheter.
Links
Organization
- CEO
- MJ
Mark James Davis1975
- Chairman of the board
- RE
Ronald Eric Long1947
- Years since formation
- 31 years
- since Feb 20, 1995
- Type
- Limited company
- VAT registered
- Yes
- Number of employees
- 7
Ownership
- Number of shares and share classes
- 260
- 1 share class
- Total number of shareholders
- 1
- person
Financials
- Total operating income 2025
- 22,526,596
- NOK
- Annual total result 2025
- -12,766,616
- NOK
- Total equity 2025
- 5,202,310
- NOK
Last update: Oct 26, 2026
Management
Management / administration
| Name | Role | Shares |
|---|---|---|
MJ 1975 | Managing Director/CEO | - |
Board
| Name | Role | Shares |
|---|---|---|
RE 1947 | Chairman | - |
| Board Member | - |
Others
| Name | Role | Shares |
|---|---|---|
| Auditor | - | |
| Accountant | - |
Last update: Oct 26, 2026
Ownership
Company shareholders
| Name | Share class | Total number of shares | Share |
|---|---|---|---|
| Ordinary shares | 260 | 100 % |
Last update: Sep 25, 2026
Financials
in NOK
Summary
| Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
Total operating income | 22,526,596 | 33,815,508 | 37,961,288 | 28,800,535 | 25,522,592 |
Annual Total Result | -12,766,616 | -1,524,951 | 3,432,744 | -4,498,619 | -5,160,746 |
Total assets | 22,609,070 | 23,262,497 | 24,320,562 | 23,729,166 | 28,490,952 |
Total liabilities | 17,406,760 | 5,293,571 | 4,826,685 | 7,668,033 | 7,931,199 |
Total equity | 5,202,310 | 17,968,926 | 19,493,877 | 16,061,133 | 20,559,752 |
P&L
| Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
Total operating income | 22,526,596 | 33,815,508 | 37,961,288 | 28,800,535 | 25,522,592 |
Total operating costs | 34,719,101 | 36,267,242 | 35,199,146 | 33,811,036 | 30,022,783 |
Operating result | -12,192,505 | -2,451,734 | 2,762,142 | -5,010,501 | -4,500,192 |
Financial income/costs | -539,773 | 951,001 | 687,376 | 455,121 | -3,387 |
Profit before tax | -12,732,278 | -1,500,733 | 3,449,518 | -4,555,380 | -4,503,578 |
Total tax & extraordinary income/cost | 34,338 | 24,218 | 16,774 | -56,761 | 657,168 |
Annual Total Result | -12,766,616 | -1,524,951 | 3,432,744 | -4,498,619 | -5,160,746 |
Balance overview
| Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
Total fixed assets | 12,964,914 | 1,107,237 | 1,260,914 | 2,123,507 | 3,118,943 |
Total current assets | 9,644,156 | 22,155,260 | 23,059,648 | 21,605,659 | 25,372,008 |
Total assets | 22,609,070 | 23,262,497 | 24,320,562 | 23,729,166 | 28,490,952 |
Short term debt | 17,406,760 | 5,293,571 | 4,826,685 | 7,668,033 | 7,931,199 |
Long term debt | 0 | 0 | 0 | 0 | 0 |
Total liabilities | 17,406,760 | 5,293,571 | 4,826,685 | 7,668,033 | 7,931,199 |
Contributed capital | 104,000 | 104,000 | 104,000 | 104,000 | 104,000 |
Retained earnings | 5,098,310 | 17,864,926 | 19,389,877 | 15,957,133 | 20,455,752 |
Total equity | 5,202,310 | 17,968,926 | 19,493,877 | 16,061,133 | 20,559,752 |
Total equity and liabilities | 22,609,070 | 23,262,497 | 24,320,562 | 23,729,166 | 28,490,952 |
Classification
21st company classification
BETA
Small company
Type of organization
Limited company
Classification of institutional sector
INNL
Domestic sectors
A_IKKE-FIN
Non-financial corporations
2100
Private non-financial incorporated enterprises
Standard industrial classification